Practice Essentials
 | Current and Future Perspectives in the Treatment of High-risk MDS CME, CPE Richard Stone, MD | |
| Release Date: May 31, 2021 Expiration Date: May 31, 2022 | ||
Join Dr. Richard Stone as he explores current and future treatments for high-risk myelodysplastic syndromes (MDS). Topics will include risk assessment and stratification systems, venetoclax as monotherapy or in combination with hypomethylating agents, the implications of TP53 mutations, and the role of investigational agents in high-risk MDS, including oral cedazuridine/decitabine, enasidenib, pevonedistat, APR-246, magrolimab, and sabatolimab. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc. | ||
| View Only, No Credit | ||
 | Treatment Protocols for Patients with Symptomatic Low-risk MDS CME, CPE Rami S. Komrokji, MD | |
| Release Date: December 09, 2020 Expiration Date: December 09, 2021 | ||
In this activity, Dr. Rami Komrokji explains how to manage patients with lower-risk MDS. He will take you through diagnosis, risk stratification, and tailoring treatment. He will also cover patients with genetic mutations, ring sideroblasts, and cytopenias. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc. | ||
| View Only, No Credit | ||